Relexxii

Vertical Pharmaceuticals is showcasing Relexxii at APA 2026. Here's the context, what to ask at the booth, and where Videra fits in the conversation.

CompanyVertical Pharmaceuticals

StatusAPPROVED (2022)

IndicationADHD (adults & pediatric 6+)

MechanismCNS stimulant (dopamine/norepinephrine releaser)

Context

Why Vertical Pharmaceuticals is promoting this at APA

Relexxii is Vertical's sole psychiatric product — osmotic pump delivery methylphenidate positioned against generic Concerta. At APA, they'll emphasize the consistent delivery profile and any pricing/access advantages.

Booth Conversation

Talking points for the conversation

Ask about: Formulary wins vs. generic Concerta; how prescribers perceive delivery system differentiation; real-world symptom control throughout the day; market share trajectory. Straightforward product conversation.

Videra · Med Affairs Angle

Where Videra fits

ePRO+ captures real-world ADHD symptom control profiles throughout the day — demonstrating osmotic pump consistency advantage. VoiceVitals measures attention and cognitive performance through linguistic biomarkers.

Let's pick this up at the booth.

Set up a follow-up with Vertical Pharmaceuticals's team and Videra Health.

Email Ryan Roberts →